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Summary
Objective: This study focuses on the question of whether
the pulmonary response to inflammatory stimulation,
resulting in increased vascular resistance and permeability,
could be attenuated by short-term infusion of triglycerides
containing omega (n)-3 fatty acids. The parenteral
application of a lipid emulsion prepared from fish oil
(Omegavenös®) was tested in comparison with a soy oil
preparation (Lipovenös®). The hypothesis was that
infusion of eicosapentaenoic acid (EPA), the major n-3
fatty acid contained in fish oil, may interfere with eicosanoid
synthesis in such a manner that stimulation results in the
release of the less vasoconstrictive and permeability
enhancing metabolites of EPA instead of those of
arachidonic acid (AA).
Design: Isolated lungs from anaesthetised rabbits were
ventilated and recirculation-perfused (200 ml/min) with
250 ml cell-free buffer solution to which either 2.5 ml
saline (controls, n=3), 2.5 ml Lipovenös® 10% (n=11), or
2.5 ml Omegavenös® 10% (n=13) were added. To study
the alterations of pulmonary vascular permeability in states
of inflammatory stimulation, lungs of each group were
stimulated with calcium-ionophore A23187 (1 µM). The
capillary filtration coefficients (C
fc
), as an index of
permeability, were determined before and after
administration of A23187 at 30-minute intervals during
an observation period of 210 minutes. To study lipid effects
on neutrophil-mediated inflammatory reactions, the same
protocol was performed in additional experiments in which
isolated human polymorphonuclear (PMN) leukocytes
(108) were added to the perfusion fluid. For analysis of the
5-lipoxygenase mediator profile, perfusate samples were
taken at 1-hour intervals.
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Main results: Baseline values of C
fc
 (0.23± 0.01 g.min-1.
mmHg-1.100 g-1) were comparable in all groups. Calcium-
ionophore challenge induced a several-fold increase in C
fc
which was significantly (p<0.05) attenuated in the
Omegavenös®-perfused lungs compared to the
Lipovenös® group. The vascular reactions during
Omegavenös® perfusion were accompanied by a reduction
of tetraen-leukotrienes and a moderate increase in pentaen-
metabolites.
Conclusion: The data demonstrate that altering the
eicosanoid precursor availability by infusion of n-3 fatty
acids a protective effect is exerted on the pulmonary
vascular reaction to inflammatory stimulation.
Introduction
Since the epidemiological studies of Bang and Dyerberg,1,2
which showed that Eskimos have low rates of coronary heart
disease and cancer, growing interest has been focused on the
importance of eicosapentaenoic acid (EPA) in the prevention
of cardiovascular diseases. These findings, confirmed in
subsequent studies in fish-eating populations,3,4 point towards
the antithrombotic and anti-inflammatory properties of EPA,
the major n-3 fatty acid contained in fish oil. In accordance
with these observations, dietary supplementation with large
amounts of fish oil was described to result in clinical
improvement of chronic inflammatory diseases such as
ulcerative colitis and psoriasis.5-7 The central question
addressed in the present study is whether short-time infusion
of n-3 fatty acids might be a putative therapeutic regimen for
modulating acute inflammatory reactions, ie increased
pulmonary permeability, the major pathophysiological event
occurring during the development of ARDS.
The anti-inflammatory effects, observed after long-term
administration of dietary n-3 fatty acids in animal and human
studies, seem to be due to an augmented generation of EPA-
derived eicosanoids.8-10 Diets supplemented with n-3 fatty
acids alter the composition of cell membranes in such a way
that n-3 fatty acids partially replace n-6 fatty acids in the
membrane of almost all cells, ie erythrocytes,11 neutrophils,12
platelets,13,14 endothelial cells, monocytes and brain and liver
cells,15 resulting in an enhanced release of products derived
from EPA with an attenuated spectrum of biological activity
compared to those derived from AA.16-17 Furthermore, the
formation of platelet activating factor (PAF), which has a
wide range of pro-inflammatory properties, is also reduced by
EPA through interference with the turnover of the PAF
precursor pool.18
Interference with eicosanoid synthesis by altering the
eicosanoid precursor availability seems to be a feasible
mechanism, since eicosanoids are derived from essential fatty
acids which must be provided in the diet.19 AA is the major
substrate in mammals for the production of biologically active
eicosanoids via the cyclooxygenase and lipoxygenase
pathways. EPA competes with AA for prostaglandin and
leukotriene synthesis on the cyclooxygenase and on the 5-
lipoxygenase level, thus modulating the production of diene-







tetraene-leukotrienes (for example LTC
4
) derived from AA in







) and pentaene-leukotrienes (for example
LTC
5
) derived from EPA.19 In recent in vitro studies which
focused on the kinetics of the incorporation and metabolism
of n-3 fatty acids, we demonstrated that n-3 fatty acids were
rapidly integrated into the exchange pool of free fatty acids in
the lung tissue and were metabolised even after a preceding 3-
hour lipid infusion.20
Considering that eicosanoids play an important role in the
pathogenesis of pulmonary oedema following trauma, shock
and sepsis,21 it should be evaluated whether or not infusion of
n-3 fatty acids exerts a protective effect on pulmonary vascular
reaction and mediator release due to inflammatory stimulation.
For this purpose, the parenteral application of a lipid emulsion
prepared from fish oil was compared with a soy oil preparation
in a reproducible animal model. From the clinical point of
view, the intravenous route may be advantageous in order to
combine parenteral nutrition with anti-inflammatory
intervention. In addition, slow kinetics and limited availability
of dietary fatty acids for effective modulation of inflammatory
mediator profiles can thus be surmounted. Calcium-ionophore
A23187, a non-specific inflammatory stimulus, was used to
simulate an inflammatory response with enhanced eicosanoid
synthesis. Calcium-ionophore induces an intracellular calcium
influx, thereby activating the enzyme phospholipase A
2
 which
liberates the precursor fatty acids for eicosanoid synthesis
from membrane phospholipids. Alterations of pulmonary
vascular permeability were monitored by repetitive
determinations of the capillary filtration coefficient (C
fc
) and
compared with the observed changes in the leukotriene profile.
Materials and methods
The lung model
The techniques of preparing and perfusing isolated rabbit
lungs have been previously described in detail.22 Standard
breed rabbits (ortictolagus caniculus) of either sex weighing
3,100±196 g (mean±SD) were anaesthetised with pentobarbital
sodium 60-80 mg/kg and anticoagulated with heparin-sodium
1000 U/kg injected in the ear vein. The trachea was cannulated
and the rabbits were mechanically ventilated by means of a
Starling pump (B Braun, Melsungen, Germany). The thorax
was opened via the diaphragm and, after a median sternotomy,
catheters were inserted into the pulmonary artery and the left
atrium, passing through the aortic and mitral valves. The lung
and heart organ preparation was isolated and suspended from
a weight transducer (Hottinger, Baldwin Meßtechnik Type
U1, Darmstadt, Germany) in a temperature-controlled (37°C)
and humidified chamber. After the cannulation procedure,
the lungs were perfused with 250 ml Krebs Henseleit hydroxy-
ethyl-starch buffer solution (KHHB) by a roller pump
(Masterflex® 7566-10, Cole Palmer Instruments Co, Chicago,
USA) at a constant volume inflow of 200 ml/min in a
recirculating system. The lungs were ventilated with 4% CO
2
in air (frequency 25/min, tidal volume 30 ml, PEEP 0.5-1.0
cmH
2
O) and, in order to avoid atelectasis formation,
intermittently flushed by increasing the expiratory pressure
up to 3 cmH
2
O for three inspirations. The pulmonary arterial
(PAP), venous (PVP) and airway pressures (AP) were
continuously recorded via Statham strain gauge transducers.
Using two separate perfusion circuits, the perfusion fluid was
exchanged for fresh buffer 2 minutes after the beginning of
the extracorporeal circulation and again after increasing the
flow up to 200 ml/min (30 minutes).
After another 30-minute steady-state period, these lungs
had a constant mean PAP of 7.5-8.5 mmHg (zero-referenced
at the hilum); PVP was set at 0 mmHg. The only lungs
selected for the study were those that showed a homogenous
white appearance with no signs of haemostasis or oedema
formation, and which were completely isogravimetric during
the steady-state period. In pilot experiments, the perfusion
with KHHB has been documented to maintain integrity of the
microcirculation for more than 5 hours in our model, which
was assessed by measurements of PAP and weight gain, by
biochemical analysis (LDH, AA-metabolites, histamine) as
well as by ultrastructural studies. During the observation
period, neither significant alterations in LDH, eicosanoids
and histamine release, nor structural abnormalities (for
example, destruction of endothelial or epithelial cells) were
found.
Measurements
The PAP, PVP, AP and weight gain (as an indicator of
extravascular lung water) as well as the pH value were
continuously recorded (Rikadenki, Kogyo, Tokyo, Japan).
The oncotic pressure (Onkometer BMT921, Dr Karl Thomae
GmbH, Biberach, Germany) in the perfusate was determined
at 30-minute intervals.
Experimental protocol
The lung preparations were randomly assigned to the different
groups. To study alterations of pulmonary vascular
permeability after incorporation and metabolisation of the
different lipid emulsion, either 2.5 ml Lipovenös® 10% (n=11)
or 2.5 ml Omegavenös® 10% (n=13) corresponding to 70 mg
lipid/kg body weight, were added to the perfusion fluid. Lungs
in which 2.5 ml saline was injected into the perfusate served
as controls (n=3). In order to investigate selectively lipid
metabolisation via the lipoxygenase pathway, the
cyclooxygenase-blocker diclofenac (10 µg/ml) was applied.
Dimetidenmaleate and cimetidine were injected into the
perfusion fluid to exclude unspecified histamine-reactions
which might interfere with leukotriene-induced reactions on
vascular permeability. After a 30-minute isogravimetric
steady-state period, the first perfusate sample was drawn for
measurements of baseline values. The baseline capillary
filtration coefficient (C
fc
) was determined by venous pressure
elevation of 7.5 mmHg. After the first C
fc
 measurement, all
lungs except controls were stimulated with A23187 yielding
in a final concentration of 1 µmol/l. The used dosage of
calcium-ionophore A23187 was selected to investigate acute
effects due to unspecified inflammatory stimulation on
pulmonary vascular resistance and permeability and mediator
release. In preliminary dose-response studies (n=8), this
amount was shown to induce inflammatory reactions such as
significant histamine release and eicosanoid generation, a
marked activation of granulocytes with elastase release, and a
moderate increase in pulmonary vascular resistance and
microvascular permeability. Higher doses resulted in
overwhelming pressure increases followed by immediate
alveolar flooding and severe barotrauma of the lung, whereas
lower doses produced an insufficient mediator release hardly
detectable in the perfusate by the used methods.
During and after the following 210-minute lipid perfusion
period, C
fc
 was measured at 30-minute intervals. In order to
study lipid effects on neutrophil-mediated inflammatory
reactions, the same protocol was performed in additional
experiments in which isolated washed human PMN-leukocytes
(156±13 × 106) were added to the perfusion fluid prior to
injection of Lipovenös® 10% (n=4) and Omegavenös® 10%
(n=4), respectively. Leukotriene generation was analysed in
these experiments before, as well as 60, 120 and 180 minutes
after A23187-stimulation. The elastase inhibitor Eglin (r-
(Ac)Eglin, Ciba Geigy, Basel, Switzerland) was added to the
perfusate prior to ionophore challenge. This served to inhibit
protease-induced effects on vascular permeability which might
mask effects due to the different mediator profile in the
Lipovenös®- and Omegavenös®-perfused lungs.
In additional pilot experiments, it was tested whether
perfusion with either Lipovenös® (n=6) or Omegavenös®
(n=6) per se led to vascular reactions and mediator release in
our model. Since increasing doses from 1 ml up to 10 ml of
each lipid emulsion per 250 ml perfusate induced neither
alterations in vascular tone and permeability nor mediator
generation, the observed effects after calcium-ionophore
stimulation could be mainly attributed to the different spectrum
of metabolites.





 expresses the proportionality between net fluid filtration
and the balance of hydrostatic and oncotic forces across the
microvascular membrane. The technique of gravimetrically
determining C
fc
 used in the present study was developed by
Drake, Smith and Gabel in intact dog lungs.23 C
fc
 was
determined from the slope of lung weight change per time
after venous pressure elevation up to 7.5 mmHg. The
hydrostatic challenge was maintained over a period of 7
minutes for each C
fc
 estimation. Previous experiments showed
that this procedure of venous pressure elevation did not
enhance the subsequent weight gain. Both the ventilation and
flow (at 200 ml/min) were maintained during hydrostatic
challenge. The tangent to the slope of the slow phase of
weight gain was taken, beginning at 2 minutes until 7 minutes
after onset of the pressure rise. The rapid weight gain during
the first 2 minutes and the corresponding weight loss after the
hydrostatic challenge was considered a vascular filling effect.24
C
fc
 was obtained as the slope of the tangent relating the
average weight change per time induced by pressure elevation
related to the calculated pulmonary capillary pressure (PCP)
(expressed in ml.min-1.mmHg-1.100 g wet weight-1) in each
group. The capillary pressure was estimated according to
Drake et al:25
PCP = PVP + 0.44 (PAP – PVP)
The filtrate was assumed to have unitary density. The wet
lung weight was calculated from the body weight (BW) of the
animal using BW (g) × 0.0024. In preliminary experiments
this factor had been determined as the ratio between the wet
weight of the lung, corrected for the vascular volume by
previous application of 125I-albumin, and the BW of the rabbits
(standard race and breed set).26 This had turned out to be a
more precise method than draining the vascular compartment,
weighing the lungs at the end of the experiment, and thereby
subtracting the measured overall weight gain. During pressure
elevation up to 7.5 mmHg to determine C
fc
, the bulk of the
lungs were under zone III conditions (peak inflation pressure
3.5-5.0 mmHg), thus major influence of changes in surface
area on C
fc
 estimations were improbable.
Preparation of PMN-leukocytes
Granulocytes were prepared according to a method of Hjorth27
using Percoll®.
Analysis of leukotriene generation
Reversed phase high pressure liquid chromatography (HPLC)
was used for separation and quantification of tetraen- and
pentaen-leukotrienes. Released leukotrienes were extracted
from a 10 ml aliquot of lung perfusion fluid each time by
octadecyl solid phase extraction columns (SEP-PAK C
18
cartridges, Waters Associates, Milford, USA), as described.28
Conversion into methyl esters was performed by addition of
freshly prepared diazomethane in diethyl ether. Leukotrienes
were then eluted with 1 ml methanol and the solvent was
evaporated. The residues were taken up in 0.05 ml of methanol
and chromatographed isocratically, using reversed phase
HPLC on a Octadecylsilyl column (particle size: 5 µm
[Hypersil, Fa. Marchery-Nagel, Düren, Germany], mobile
phase: methanol/water/acetic acid, 72.9:27.3:0.16, pH 4.9).
Leukotrienes were conventionally detected at 270 nm
(Spectroflow 773 Absorbance detector, Kratos analytical
instruments, Karlsruhe, Germany). All obtained data are given
in pmol/ml of perfusion fluid. The retention times of the LT
were compared with the retention times of authentic LT-
standards (Fa. Paesel, Frankfurt/M, Germany).
Materials
A cell- and plasma-free perfusion medium was used in the
present study in order to avoid the complex interactions with
different circulating cells which may mask direct effects on
vascular tone and mediator release. The perfusate consisted
of a Krebs-Henseleit buffer solution with additional human
albumin (Rhodalbumin® 20%, Merieux GmbH, Leimen,
Germany) in order to maintain a colloid oncotic pressure
between 23-25 mmHg, yielding in final concentrations of:
albumin 20 g/l; Na+ 138 mmol/l; K+ 4.5 mmol/l; Mg2+ 1.33
mmol/l; Cl- 135 mmol/l; Ca2+ 2.38 mmol/l; glucose 12 mmol/l;
HCO
3
- 12 mmol/l. The osmolality was approximately
330 mOsm/kg (Mikro-Osmometer, Roebling Meßtechnik,
Berlin, Germany). The pH of the buffer solutions was adjusted
to 7.4 with 0.1 M NaHCO
3
 just before cannulation. Effects
due to endotoxin contamination of the plasma-free perfusate
can be excluded in our model as assessed by previous
experiments. Calcium-ionophore A23187 was purchased from
Sigma Chemical (Munich, Germany).
The lipid emulsions Omegavenös® 10% prepared from
fish oil and Lipovenös® 10% produced from soy oil were a
generous gift from Dr E Schlotzer, Fresenius AG (Bad
Homburg, Germany). Both are 10% fatty acid emulsions. The
used batches of Omegavenös® 10%, rich in long chain n-3
fatty acids, yielded in final concentrations in the emulsion:
eicosapentaenoic acid (C20:5n3) 19 mg/ml, docosahexaenoic
acid (C22:6n3) 25 mg/ml, palmitic acid (C16:0) 12 mg/ml,
stearic acid (C18:0) 2.5 mg/ml, oleic acid (C18:1n9) 14 mg/ml,
linoleic acid (C18:2n6) 2.7 mg/ml, linolenic acid (C18:3n3)
0.7 mg/ml, arachidonic acid (C20:4n6) 2.2 mg/ml, other fatty
acids 27.3 mg/ml. The major components of Lipovenös®
10%, rich in n-6 fatty acids were: linoleic acid 51 mg/ml,
linolenic acid 7.2 mg/ml, oleic acid 22.4 mg/ml, palmitic acid
12 mg/ml, stearic acid 4 mg/ml and other fatty acids
10 mg/ml.
Statistical analysis
Data are presented as means±standard error of the mean (SE).
Differences between groups were tested by one-way analysis
of variance (ANOVA) followed by Scheffé’s multiple
comparison procedure. Significance was accepted at p<0.05.
This study was approved by the Animal Subject Protection
Committee of the University of Giessen. The care and handling
of animals were in accordance with the principles expressed
in the Helsinki Declaration.
Results
After an isogravimetric equilibration period either saline,
Lipovenös® or Omegavenös® was added to the perfusate.
Baseline values of PAP between 7.5 and 8.5 mmHg, and
airway pressure between 4 and 5.5 mmHg, were similar in all
groups and in agreement with our own previous studies.29,30
The initial capillary filtration coefficient (C
fc
(0)) achieved a
mean value of 0.23±0.1 g.min-1.mmHg-1.100 g-1 in all groups.
Concentrations of leukotrienes were not detectable (<0.5
ng/ml). The lungs were challenged with calcium-ionophore
A23187 (1 µM) in order to study the metabolism of n-3 fatty
acids in states of an enhanced AA turnover due to inflammatory
stimulation.
Changes in capillary filtration coefficient
Calcium-ionophore stimulation caused a gradual increase of
C
fc
 in all experimental groups and was most pronounced in the
Lipovenös®-perfused lungs. For comparison of groups the
alterations in C
fc
 were expressed as quotients, relating the C
fc
at the various time points to the baseline value C
fc
(0) (Figure
1). In the Lipovenös®-treated lungs, there was more than a
24-fold C
fc
 increase until the end of observation (210 minutes
post-A23187 injection), whereas the maximum increase in
the Omegavenös® group reached only a mean value of 15.9.
During Lipovenös® perfusion the increase in C
fc
 was
significantly higher (p<0.05) at 60, 90, 180 and 210 minutes
Figure 1 Increase in capillary filtration due to calcium
ionophore (1 µM) challenge in cell-free perfused
lungs, expressed as a quotient of Cfc at the
various time-points related to the baseline value
Cfc(0). Cfc/Cfc(0) was significantly reduced
(p<0.05) in the Omegavenös® group at 60, 90,
180 and 210 minutes. Data given are mean±SE.
* p<0.05 versus corresponding values in
Lipovenös® group.
after ionophore-challenge compared with the Omegavenös®-
treated lungs.
To investigate the effect of n-6 and n-3 fatty acids in the
presence of PMN-leukocytes, which are known to be the
main source of leukotriene production, the same protocol was
applied in further experiments after addition of PMN to the
perfusate and subsequent calcium-ionophore challenge. In
comparison with the cell-free perfused lungs similar results
were obtained in the presence of PMN-leukocytes, thus
showing a significantly blunted increase (p<0.05) of
pulmonary vascular permeability quantified as C
fc
 in the
Omegavenös®-treated lungs at 90, 120, 150, and 180 minutes
after application of A23187 (Figure 2). Perfusion with the
n-3 fatty acid emulsion resulted in a reduced increase in
capillary filtration, as evidenced by 30% lower filtration
coefficients, compared to the corresponding values in the
lungs treated with the n-6 lipid emulsion. In the presence of
neutrophils A23187 injection evoked a more rapid increase in
C
fc
 than in the cell-free perfused lungs, accompanied by an





(0)) of approximately 24 in the Lipovenös®-
and of 15 in the Omegavenös®-treated lungs, respectively,
was already reached at 180 minutes after A23187 injection.
All lungs challenged with calcium-ionophore in the presence
of PMN developed severe lung oedema before the end of the
observation period (210 minutes post-A23187 injection).
In the lipid-free perfused unstimulated controls only minor
changes in C
fc
 occurred during the whole observation period,
thus implying that repetitive hydrostatic challenges
(7.5 mmHg) for estimation of the filtration coefficient did not
severely impair lung barrier function.
The oncotic pressure and the pH measurements showed no
significant changes during the experiments in either group.
Mediator profile
The reported alterations in C
fc
 were paralleled by a different
profile of leukotriene generation in the PMN-perfused lungs.
To determine the mediator spectrum reflecting the metabolism
of the applied fatty acids, perfusate samples were analysed
during lipid perfusion at hourly intervals. Since AA and EPA
are precursors of metabolites which differ in one double
bond, lipoxygenase products were differentiated in the AA-
derived tetraene- and the EPA-derived pentaene-leukotrienes.
The exemplary measurements of leukotrienes by HPLC







 appear very early (after 1 hour) in the perfusate of the
Omegavenös®-perfused lungs, thus implying that n-3 fatty
acids had been metabolised after short-term infusion. LTD
5
could only be measured in insignificant quantities. In contrast
to the Omegavenös®-treated lungs, no detectable amounts of
pentaene leukotrienes were found during Lipovenös®







) found in the Omegavenös®-
treated lungs. The rapid rise in 5-series LTs in the
Omegavenös® group with EPA:AA product ratios surpassing
10-30% was paralleled by a substantial decrease in 4-series
leukotrienes (Figure 4). The total amount of tetraene-LTs was
reduced to less than 40% of LT-concentrations obtained in the
Lipovenös®-perfused lungs. The most convincing suppression
of mediator generation was detectable in LTE
4
 concentrations
(Figure 4d). Lipovenös® perfusion resulted in mean LTE
4





to calcium ionophore (1 µM) challenge in the
presence of PMN-leukocytes (156±13 × 106)
perfused with either Lipovenös® 10% (n=4)
or Omegavenös® 10% (n=4). Data given are
mean±SE. * p<0.05 versus corresponding
values in Lipovenös® group.








ionophore stimulation, measured (HPLC) in
the perfusion fluid of lungs perfused with
Omegavenös®10% (n=4). In contrast to the
Lipovenös®-treated lungs in which no 5-series







 appeared after 1 hour in the perfusate in
the Omegavenös® group. Data given are
mean±SE.
the pathogenesis of pulmonary oedema following trauma,







 and hydroxyeicosatetraenoic acids
have been shown to impair lung barrier function in numerous
experimental studies investigating ARDS.31,32 Further evidence
of the involvement of AA lipoxygenase products in the
development of ARDS is obtained from the beneficial effects
of administered lipoxygenase inhibitors in animal models.33
Recently, dietary enrichment of PMN phospholipid pools
with n-3 fatty acids has attracted attention as a putative
therapeutic regimen for mitigating PMN- and eicosanoid-
related inflammatory events.34,35 Neutrophils, isolated after
intake of an n-3 fatty acid-supplemented diet, exhibited a
several fold increase in EPA-derived 5-lipoxygenase products
associated with a moderately reduced generation of AA-
derived leukotrienes upon in vitro ionophore challenge. A
variety of responses to inflammatory stimuli, including
chemotaxis, were noted to be diminished in these PMN.36
LTB-5 generated in EPA-enriched PMN possesses more than
Figure 4 a) to d) Comparison of AA-derived 5-lipoxygenase product formation upon calcium-ionophore stimulation
in the lungs perfused with either Lipovenös® 10% (n=4)  or Omegavenös® 10% (n=4) 
. . . . . .. . . . . .. . . . . .. . . . . .. . . . . . . Tetraene-
leukotrienes were substantially reduced in the Omegavenös® group compared with Lipovenös®-perfused
lungs. Data given are mean±SE.
production of 876 pmol/ml, while the corresponding value in
the Omegavenös®-perfused lungs reached only mean values
of 152 pmol/ml. Equally, LTC
4
 release was reduced to 13% of
mean concentrations (42 pmol/ml versus 324 pmol/ml)
detected under Lipovenös® perfusion (Figure 4b). Similarly,
Leukotriene B
4
 generation was moderately suppressed after
application of Omegavenös® solution (Figure 4a).
Consequently, the application of Omegavenös® leads to a
markedly reduced production of tetraene-LTs and a rapid rise
in the less permeability enhancing pentaene-LTs due to
calcium-ionophore challenge. These effects were associated
with a significantly attenuated increase in capillary filtration.
Exemplary radioimmunological measurements of histamine
release into the perfusate revealed no detectable amounts in
either Lipovenös®- or Omegavenös®-perfused lungs.
Discussion
Arachidonic acid metabolites have long been implicated in
a 10-fold reduced chemotactic and PMN activating capacity
compared to LTB
4




Based on this reasoning, this study was designed to
investigate whether short-term infusion (3 hours) of n-3 fatty
acids was able to influence the development of pulmonary
oedema due to acute inflammatory stimulation, and thus might
be of therapeutic interest in the treatment of critically ill
patients. For this purpose, the effect of a fish oil-derived lipid
emulsion on vascular permeability and mediator release was
tested compared with a soy oil emulsion in a reproducible
animal model. We monitored both impairment of lung barrier
function in terms of the capillary filtration coefficient and
lipid mediator profiles in response to n-3 versus n-6 lipid
supplementation. In view of the clinical use of these lipid
emulsions, the parenteral application was tested to overcome
slow kinetics and limited availability of dietary fatty acid
supplementation for modulation of inflammatory mediator
spectrum. The synthetic calcium-ionophore A23187 was used
in the present study as it is representative of a great variety of
exogenous and endogenous stimuli characteristically found
in sepsis and trauma which induce the synthesis of arachidonic
acid metabolites. A23187 increases intracellular Ca2+ levels
by opening calcium channels in the cell membrane analogous
to the effects of pore-forming bacterial toxins (for example,
Staphylococcal a-toxin, E coli hemolysin, Pseudomonas
aeruginosa cytotoxin).38,39
The generation of eicosanoids, caused by a broad spectrum
of different stimuli, seems to be a common pathophysiological
mechanism leading to increased vascular tone and disturbances
of epithelial and endothelial barrier function in the
microcirculation of the lung and other organs. Since this
pathophysiological concept seems to be of significance in
various species, including humans, experimental studies on
animal models may contribute to elucidate the complex
interactions involved in the pathogenesis of ARDS and multiple
organ failure. In particular, it could be demonstrated that the
pattern of the generated eicosanoids in the pulmonary
circulation and their vascular reaction is comparable in rabbits
and human beings.40,41
Summarising the current data, there is evidence that the
EPA-enriched fish oil emulsion Omegavenös® exerts a
protective effect on pulmonary vascular permeability due to
inflammatory stimulation. This was indicated by significantly
reduced capillary filtration and a decrease in leukotriene
production in the Omegavenös®-perfused lungs compared
with those lungs treated with Lipovenös®. Since calcium-
ionophore injured lungs with no lipids added to the perfusate
showed a significantly higher increase in pulmonary arterial
pressure and oedema formation compared to Omegavenös®-
treated lungs in our previous study,20 a protective effect of n-3
fatty acids on inflammatory vascular reaction can be assumed.
In the present study, the vascular reaction in terms of alterations
of C
fc
 was investigated in the absence and presence of PMN.
Both experimental designs gave qualitatively identical data,
but oedema formation was more enhanced when leukocytes
were added to the perfusate. This might be explained by an
increased mediator release into the perfusate since leukocytes
are potent leukotriene-producing cells. LT measurements in
cell-free perfused lungs which revealed quantities below the
detection limits of the used method supported this assumption.
For this reason the leukotriene spectrum was analysed in the
perfusion fluid of PMN perfused lungs. We found a markedly
reduced synthesis of AA-derived 4-series LTs and a moderate
increase in EPA-derived 5-series lipoxygenase products in
the Omegavenös®-perfused lungs. These results are in
accordance with previous findings investigating leukotriene
production of isolated neutrophils after intake of n-3 fatty
acids.35,36 In contrast to the Omegavenös®-perfused lungs, no
detectable concentrations of 5-series leukotrienes were found
in the Lipovenös®-treated lungs, whereas the total amount of
tetraen LTs reached considerably higher values. Blunted
oedema formation may be related to the synthesis of
biologically less active EPA-derived 5-lipoxygenase products
and to the inhibition of the inflammatory functions mediated
by 4-series leukotrienes, respectively.
Since effects on vascular permeability due to histamine
release, which was not detectable in either group, or due to the
lipid emulsion itself seem unlikely, the reduced oedema
formation in the lungs pretreated with Omegavenös® could
be attributed to the less harmful biological properties of the
EPA-derived leukotrienes.
When analysing the biochemical and physiological results
in our model, it has to be taken into account that Omegavenös®
contains not only EPA but also AA, as well as its precursors,
in considerable amounts which may partially mask the effects
of EPA on pulmonary vascular permeability and mediator
generation.
Besides the described beneficial effects on pulmonary
capillary filtration in our model, the effects of n-3 fatty acids
on leukocyte endothelial cell interactions have been evaluated
in in vitro and in vivo studies.42,43 It has been suggested that
dietary fish oil prevents leukocyte/endothelium interaction
through the inhibition of leukotriene biosynthesis of series 4.
Evidence is provided that LTB
4
 induces leukocyte adhesion
to the endothelium through upregulation of CD11b/CD18
adherence receptors on the leukocyte surface.44 EPA-derived
LTB
5
, however, is less potent in upregulating CD11b/CD18
by two orders of magnitude.37 EPA attenuates leukocyte/
endothelium interactions not only by inhibition of adhesion-
promoting mediators but also by enhanced generation of
antiadhesive forces, particularly by increased prostacyclin
formation. In addition, EPA derived cyclooxygenase products
have generally been shown to exert less vasoconstrictive and
thrombotic effects than the corresponding 2-series prostanoids,
and may therefore contribute to the overall anti-inflammatory
potency of n-3 fatty acids.
Although this study investigates only a part of the broad
spectrum of biological effects induced by EPA under defined
experimental conditions, the results suggest that n-3 fatty
acids, apart from the nutritional aspect, may be a useful
therapeutic approach in critically ill patients. In view of the
current data, it can be concluded that the infusion of EPA-
enriched lipid emulsion is capable of reducing pulmonary
vascular permeability, presumably due to an altered mediator
profile of 5-lipoxygenase products. Supplementation of n-3
fatty acids induces a variety of further metabolic changes,
including the inhibition of oxygen radical generation and the
release of PAF and cytokines18,46 which have all been
implicated in the inflammatory response. Hence, lipid
emulsions based on fish oil may exert protective effects on the
pulmonary vasculature and, possibly, on multiple organ failure
development. From the clinical point of view, these findings
imply that the use of EPA-enriched lipid emulsions may thus
combine parenteral nutrition and an anti-inflammatory
intervention in critically ill patients.
The present study suggests that the use of n-3 fatty acids
seems to be a promising therapeutic approach for the
amelioration of acute inflammatory processes. The causal
relationship between the improvement in clinical
manifestations and measured changes in eicosanoid generation
remains to be elucidated in future studies.
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